Hepatocyte Growth Factor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)- Pipeline Review, H2 2019’, provides in depth analysis on Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Central Nervous System, Cardiovascular, Dermatology, Genito Urinary System And Sex Hormones, Hematological Disorders and Metabolic Disorders under development targeting Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

– The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AnGes Inc

Athira Pharma Inc

Helixmith Co Ltd

i2 Pharmaceuticals Inc

Kringle Pharma Inc

Minerva Biotechnologies Corp

Molecular Partners AG

Yichang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Overview

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Companies Involved in Therapeutics Development

AnGes Inc

F-star Biotechnology Ltd

Kringle Pharma Inc

M3 Biotechnology Inc

Minerva Biotechnologies Corp

Molecular Partners AG

ViroMed Co Ltd

YiChang Humanwell Pharmaceutical Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Drug Profiles

beperminogene perplasmid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

donaperminogene seltoplasmid Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FS-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy 1 to Activate HGF for Myocardial Infarction Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate HGF for Critical Limb Ischemia and Chronic Post-Operative Pain Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-100IT Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MM-201 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-0250 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NDX-1017 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NK-4 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-186 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-188 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YYB-101 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Dormant Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Discontinued Products

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Product Development Milestones

Featured News & Press Releases

Aug 20, 2018: Genopis builds team of experts to operate San Diego DNA production facility

Aug 01, 2018: ViroMed picks Sunyoung Kim, the founder and co-CEO, as sole chief executive

Jul 30, 2018: ViroMed announces publication on VM202’s MoA in regulating muscle atrophy

Jul 27, 2018: Last patient randomized in ViroMed’s VM202 phase III trial on PDPN

Jun 28, 2018: Drug based on ViroMed’s VM202 Technology Successfully Completes Phase II for Critical Limb Ischemia in China

Jun 15, 2018: Molecular Partners presents updated results from its ongoing Phase 2 combination study of its lead oncology drug MP0250 at EHA in Stockholm

May 30, 2018: ViroMed Announces Publication of VM202s MoA in Nerve Regeneration

May 23, 2018: VM BioPharma Presents at Pain Therapeutics Conference in UK

May 16, 2018: Molecular Partners to present final MP0250 Phase 1 data at ASCO Annual Meeting 2018

Apr 21, 2018: Molecular Partners presented preliminary results from the ongoing phase 2 study of MP0250 at the European Myeloma Network Meeting in Turin

Apr 17, 2018: ViroMed Announces Publication of VM202's MoA in Reducing Neuropathic Pain

Apr 17, 2018: ViroMeds DPN Clinical Trial Passes 70% Point in Patient Randomization

Apr 12, 2018: AARP Calls ViroMed’s VM202 “Hope” for Peripheral Neuropathy

Apr 05, 2018: Molecular Partners to present MP0250 clinical abstract at the AACR Annual Meeting 2018

Jan 22, 2018: AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AnGes Inc, H2 2019

Pipeline by Athira Pharma Inc, H2 2019

Pipeline by Helixmith Co Ltd, H2 2019

Pipeline by i2 Pharmaceuticals Inc, H2 2019

Pipeline by Kringle Pharma Inc, H2 2019

Pipeline by Minerva Biotechnologies Corp, H2 2019

Pipeline by Molecular Partners AG, H2 2019

Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H2 2019

Pipeline by Yooyoung Pharm Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports